REDWOOD CITY, Calif., May 29, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June:
- Kim Popovits, Genomic Health's Chairman, Chief Executive Officer and President, will present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 4:00 p.m. ET in New York City; and
- Dean Schorno, Genomic Health's Chief Financial Officer, will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5 at 10:40 a.m. PT in Palos Verdes, Calif.
To access the live and subsequently archived webcast of the presentations, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the beginning of the presentations to allow for any necessary software downloads. Archived replays will be available for three months beginning 24 hours after the live presentations.
About Genomic Health Genomic Health
, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions. The company's lead product, the Oncotype
breast cancer test, has been shown to predict the likelihood of chemotherapy benefit
as well as recurrence in invasive breast cancer
and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype
DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of March 31, 2012
, more than 10,000 physicians in over 65 countries had ordered more than 275,000 Oncotype
DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California
with European headquarters in Geneva, Switzerland
. For more information, please visit, www.GenomicHealth.com
. To learn more about Oncotype
DX tests, visit: www.OncotypeDX.com
Forward Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies; the ability of any tests the company may develop to optimize cancer treatment; the ability of the company to develop additional tests in the future; the applicability of clinical study results to actual outcomes; our ability to develop and launch a test for prostate cancer in 2013; the scope, success or results of clinical trials and the timing of such activities; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.